Gene sequencing test maker Illumina Inc. said Sunday that its board has accepted the resignation of its CEO and director, Francis deSouza, effective immediately.
Charles Dadswell, senior vice president and general counsel, has been named interim CEO, while the board conducts a search for a new CEO. Illumina said deSouza, who has been with the company since 2013 and was named CEO three years later, will stay on in an advisory capacity until July 31.
“Illumina’s technology remains at the forefront of DNA sequencing and has continued to set the pace for the industry,” Illumina's board chair, Stephen P. MacMillan, said in a statement. “We are confident Illumina can continue to execute on its goals, while we conduct and complete a CEO search process.”
The company, based in San Diego, said the board is looking at internal and external candidates.
The resignation comes as Illumina has been locked in a monthslong heated battle with activist investor Carl Icahn, over its $7.1 billion acquisition of cancer test maker Grail that has faced regulatory hurdles. Icahn had urged shareholders to vote out its chairman, John Thompson, and deSouza. Company shareholders voted out Thompson in late May.
Jeremy Fox-Geen, the Chief Financial Officer at Circle, joins Cheddar for a one-on-one interview as the company's stock surges on its first day of trading.
A unanimous Supreme Court has made it easier to bring lawsuits over so-called reverse discrimination, siding with an Ohio woman who claims she didn’t get a job and was demoted because she's straight.
Mike Miedler, CEO of Century21 Real Estate, on why home prices are expected to drop. And what else you need to know about the real estate market right now!
SukuPay CEO, Yonathan Lapchik, discusses the app's historic milestone, becoming the first crypto infrastructure in a leading bank app in Latin America.
